Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines

Mehra, Sukvarsha; Messner, Hans A.; Minden, Mark D.; Chaganti, R. S. K.

doi:10.1002/gcc.10025

Cited by 59 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OCI-LY3, OCI-LY10, SUDHL2, U2932 and HBL1 lack the t(14;18) and were previously classified as ABC type. 2,[21][22][23] The human bone marrow stromal cell line HS-5 was purchased from ATCC.…”

Section: Cell Linesmentioning

confidence: 99%

Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation

et al. 2010

View full text Add to dashboard Cite

Hedgehog (HH) signaling is important in the pathogenesis of several malignancies. Recently, we described that HH signaling proteins are commonly expressed in diffuse large B-cell lymphoma (DLBCL); however, the functional role of HH pathway in DLBCL has not been explored. Here, we assessed the possibility that HH pathway activation contributes to the survival of DLBCL. We found that HH signaling inhibition induces predominantly cell-cycle arrest in DLBCL cells of germinal center (GC) B-cell type, and apoptosis in DLBCL cells of activated B-cell (ABC) type. Apoptosis after HH signaling inhibition in DLBCL cells of ABC type was associated with downregulation of BCL2; however HH inhibition was not associated with BCL2 downregulation in DLBCL of GC type. Functional inhibition of BCL2 significantly increased apoptosis induced by HH inhibition in DLBCL cells of both types. We also showed that DLBCL cells synthesize, secrete and respond to endogenous HH ligands, providing support for the existence of an autocrine HH signaling loop. Our findings provide novel evidence that dysregulation of HH pathway is involved in the biology of DLBCL and have significant therapeutic implications as they identify HH signaling as a potential therapeutic target in DLBCL, in particular for those lymphomas expressing the HH receptor smoothened.

show abstract

Section: Cell Linesmentioning

confidence: 99%

Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A non-Hodgkin's lymphoma cell line with t(14;18), the OCI-LY8 cell line, was employed as positive control of reaction. 6 Amplification product length never exceeded 300 bp.…”

Section: Molecular Assaysmentioning

confidence: 99%

“…Real-time PCR sensitivity tests, performed by diluting OCI-Ly8 cell line 6 with cells from a healthy donor, showed that 2.5 BCL2/JH rearranged DNA copies were already detectable ( Figure 3). …”

Section: Real-time Pcr Quantitative Analysismentioning

confidence: 99%

Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab

Galimberti

Guerrini

Morabito

et al. 2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The main aim of this paper was to compare results of Genescan and real-time PCR methods in order to detect contamination in harvests from patients with follicular lymphoma. The secondary goal was to evaluate the efficacy of Rituximab as an in vivo purging agent. A total of 23 patients had been treated with CHOP followed by either high-dose therapy (12 patients) or high-dose plus Rituximab (11 patients), both followed by autologous transplantation. Results show that 86% of harvests from patients treated whith Rituximab were PCR-negative compared to 14.3% from controls. Real-time PCR was more sensitive than Genescan PCR; quantitative analysis revealed a correlation between the amount of contamination in the harvests and relapse after transplantation. Whereas all patients reinfused with negative aphereses achieved complete remission and showed a significantly better 5-year PFS (100%) compared to those reinfused with contaminated samples (41%), a very low amount of contamination does not appear to negatively affect outcome, suggesting that determination of a cutoff in the contamination level of harvests could be useful. Results suggest that real-time PCR is superior to Genescan PCR to select transplantable harvests and confirm the ability of Rituximab as an in vivo purging tool for follicular lymphoma. Bone Marrow Transplantation (2003) 32, 57-63. doi:10.1038/sj.bmt.1704102 Keywords: minimal residual disease; follicular lymphoma; autologous transplantation; rituximab; purging Although indolent non-Hodgkin's lymphoma (NHL) patients have a fairly long survival, they frequently experience relapses and truly curative treatments are not available to date. The most efficacious recent protocols involve high-dose therapy and anti-CD20 monoclonal antibody (Rituximab). 1 This provides some advantages, at least in terms of halting disease progression. 2 Owing to the long median survival of patients with indolent diseases, definitive clinical results of new trials may not become evident for a long period of time. Consequently, surrogate end points of survival, such as clearance of neoplastic cells from bone marrow or peripheral blood, could be provisionally considered. In the great majority of follicular lymphoma patients, the neoplastic clone is characterized by a reciprocal balanced chromosomal translocation, the t(14;18) (q32;q21), involving the bcl2 gene on chromosome 18 and the immunoglobulin heavy chain gene on chromosome 14. 3 Highly sensitive molecular methods for detecting the t(14;18) have been developed in an attempt to clarify the possible clinical role of minimal residual disease. After a program of high-dose therapy and autotransplantation, up to 68% of patients provided uncontaminated harvests. Indeed, those patients receiving PCR-negative stem cells maintained both negative molecular status and continuous clinical remission. 4 Nevertheless, these data derive from a labor-intensive and time-consuming molecular method consisting of conventional PCR assays followed by hybridization with patient-specific rad...

show abstract

“…34 OCI-Ly8 contains multiple chromosomal rearrangements involving IGH@, BCL2, BCL6, and MYC loci that have not yet been completely characterized. [53][54][55][56][57][58] J H -primed and D H -primed linear amplification of OCI-Ly8 revealed a pair of reciprocal J H -BCL2 ( Figure 4A) and D H -BCL2 ( Figure 4B) fusions, a heterozygous 6.3-kb deletion between the J H and D H translocation breakpoints, and a lower amplitude ϳ135-kb intronic BCL2 deletion that appears to be mosaic in nature. PCR amplification and sequencing of the J H and D H breakpoints confirmed that the 6.3-kb deletion is the result of an unbalanced IGH@-BCL2 translocation (see Supplemental Figure S9A at http://jmd.amjpathol.org).…”

Section: Array-based Detection Of Translocations 627mentioning

confidence: 99%

Rapid High-Resolution Mapping of Balanced Chromosomal Rearrangements on Tiling CGH Arrays

Greisman

Hoffman

2011

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

The diagnosis and classification of many cancers depends in part on the identification of large-scale genomic aberrations such as chromosomal deletions, duplications, and balanced translocations. Arraybased comparative genomic hybridization (array CGH) can detect chromosomal imbalances on a genome-wide scale but cannot reliably identify balanced chromosomal rearrangements. We describe a simple modification of array CGH that enables simultaneous identification of recurrent balanced rearrangements and genomic imbalances on the same microarray. Using custom tiling oligonucleotide arrays and genespecific linear amplification primers, translocation CGH (tCGH) maps balanced rearrangements to ϳ100-base resolution and facilitates the rapid cloning and sequencing of novel rearrangement breakpoints. As proof of principle, we used tCGH to characterize nine of the most common gene fusions in mature B-cell neoplasms and myeloid leukemias. Because tCGH can be performed in any CGH-capable laboratory and can screen for multiple recurrent translocations and genome-wide imbalances, it should be of broad utility in the diagnosis and classification of various types of lymphomas, leukemias, and solid tumors. ( J Mol Diagn

show abstract

Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines

Cited by 59 publications

References 26 publications

Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation

Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation

Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab

Rapid High-Resolution Mapping of Balanced Chromosomal Rearrangements on Tiling CGH Arrays

Contact Info

Product

Resources

About